Search your favorite song right now

1. Art Jackson's Passionate Call-to-Action for HIV Services

Art Jackson's Passionate Call-to-Action for HIV Services

He's on fire! Art Jackson, community educator of HIV prevention and care services in Fayetteville, NC, delivered a rousing call-to-action for reform in HIV/HCV testing, funds allocation, care and education at the Southern Harm Reduction and Drug Policy Network conference Thursday, September 6, 2012, in Atlanta, GA.


2. Hepatitis C: A Call to Action

Hepatitis C: A Call to Action

Every year, the Hepatitis C virus (HCV) and associated complications claim 350,000 lives. 185 million people worldwide are now thought to be infected. The virus combines with HIV to deadly effect. Yet this is a problem that largely goes unaddressed. Most of the burden of disease occurs in developing countries. And multiple barriers – including the price of diagnostics, the lack of laboratory capacity, and the cost and toxicity of treatment - are used to justify why the epidemic goes ignored. Yet HCV is curable and promisingly, the standard of care is rapidly changing. The unprecedented progresses in HCV drug development means effective, safe and tolerable oral regimens will soon be available. Lab technologies are increasingly simplified, opening new prospects for decentralised care, and for reaching more people with diagnosis and treatment, even in resource-poor settings. The time to seize this historic opportunity is upon us. In September 2012, Médecins Sans Frontières, the Open Society Foundations and Treatment Action Group, joined forces with activists, researchers, UN and government representatives to identify priority issues, share information and develop strategies to overcome the barriers that prevent access to HCV treatment in developing countries, both today and in the future. This short video highlights their concerns, and their hopes


3. Preventing Harm: Addressing and Preventing Opioid Addiction and Overdoses

Preventing Harm: Addressing and Preventing Opioid Addiction and Overdoses

May 19, 2016 Speakers: Val White, Deputy Director HIV, STD, HCV Prevention and Administration, New York State Department of Health AIDS Institute Steve Hanson, Associate Commissioner Division of Treatment and Practice Innovation, Office of Alcoholism and Substance Abuse Services (OASAS) Sharon Stancliff, MD, Medical Director Harm Reduction Coalition Opioid and prescription drug addiction and overdose are nationwide public health concerns, particularly for young people. Statistics indicate that 9 out of 10 people with addiction started using substances before they turned 18 years old and that nearly half of young people who inject heroin report abusing prescription pain killers before starting heroin. Between 2005-2014, New York State has documented a 115% increase in heroin treatment admissions in upstate New York and a 116% increase on Long Island. To combat this epidemic, New York state has a multi-sectoral response that includes legislative actions, such as the 911 Good Samaritan Law to provide legal protection against criminal action for people who seek medical assistance for an overdose, and a 2006 law that makes it legal for non-medical persons to administer Naloxone (Narcan) to prevent opioid/heroin overdose fatalities. Most recently, New York expanded access to naloxone in pharmacies across the state. In addition, county-based coalitions are working with law enforcement, the medical community, schools, businesses, civic agencies and the media to address the problem of heroin and opioid dependency comprehensively. This webcast will review the scope of the problem of heroin and prescription opioid dependence in New York State and provide an overview of state and local responses to address it.


4. HCV Action Commissioning Toolkit

  • Published: 2013-11-18T13:00:02+00:00
  • Duration: 168
  • By HCV Action


6. A Call to HCV Action

  • Published: 2013-11-15T11:10:56+00:00
  • Duration: 114
  • By HCV Action

7. Drug Pricing Policy: Panel III, Best Practices in Pricing Policy for Essential Drugs

Drug Pricing Policy: Panel III, Best Practices in Pricing Policy for Essential Drugs

October 24, 2018 This one-day conference explored the current pharmaceutical pricing landscape by bringing together leaders from the pharmaceutical industry, policymakers, legal practitioners, and scholars to engage in novel, interdisciplinary discussions to better understand current challenges and articulate best practices to address these issues. Participants assessed the current challenges presented in drug pricing policy, from development to delivery, in both the United States and international context. We also explored and articulated best practices to expand access to medicines and worked toward developing a plan for disseminating these practices more widely. Panel III: Best Practices in Pricing Policy for Essential Drugs Panelists: Peter B. Bach, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center Annette Gaudino, ​HIV/HCV Project Co-Director, Treatment Action Group (TAG) Aaron S. Kesselheim, Director, Program on Regulation, Therapeutics, and Law (PORTAL), Brigham & Women’s Hospital, and Associate Professor of Medicine, Harvard Medical School Jami Taylor, Managing Director, Stanton Park Capital Moderator: William W. Fisher, WilmerHale Professor of Intellectual Property Law, Harvard Law School, and Faculty Director, Berkman Klein Center for Internet and Society at Harvard University Learn more here: http://petrieflom.law.harvard.edu/events/details/drug-pricing-policies-in-the-united-states-and-globally